Glaxosmithkline Pharmaceuticals enterprise value

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
42,319————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
2,4932,4931,657877553
17.317.30.00.00.0
39,843————
−2,493−2,493−1,657−877−553
₹2,351.86————
2,2852,2851,9511,7781,741
10.07×————
29.44×————
30.96×————
46.98×————
Reference items — trailing FY values
3,9553,8223,7493,4543,252
1,3541,3091,177909804
1,2871,2431,111839739
—9031,290582484
8488481,267551440
—8481,267551440
—55.323.031.244.0
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

GLAXO₹2,498.00

Glaxosmithkline Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersPFIZERABBOTINDIAMEDANTAANTHEMAJANTPHARMIPCALABGLENMARKBIOCONMcap ₹42,319 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————42,318.6
- Cash, Equiv & ST Investments553.2877.41,657.12,493.02,493.0
+ Minority Interest0.00.00.017.317.3
Enterprise Value————39,842.9
Net Debt (memo)-553.2-877.4-1,657.1-2,493.0-2,493.0
EV per Share————2,351.86
Total Capital1,741.31,777.61,951.32,284.72,284.7
EV/Sales————10.07
EV/EBITDA————29.44
EV/EBIT————30.96
EV/Free Cash Flow————46.98
Reference Items — Trailing FY Values
Sales3,251.73,453.73,749.23,821.73,954.9
EBITDA804.3908.71,177.41,309.21,353.5
EBIT738.5839.01,110.61,242.81,286.7
Operating Cash Flow484.2582.01,289.9903.3—
Free Cash Flow440.2550.81,266.9848.0848.0
FCFF (free cash flow to the firm)440.1550.71,266.9848.0—
Capital Expenditure44.031.223.055.3—
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.